NPCE NeuroPace (NPCE) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001528287

Quote by TradingView

SEC filings

Insider buyers, 180 days

House members buying, 1 year

STOCK Act, US House only, disclosed up to 45 days after the trade

Funds added, last quarter

13F, latest reported quarter

NeuroPace insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for NeuroPace Inc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider

Filed

Value

Since filing

Morrell Martha

CHIEF MEDICAL OFFICER

SELL

2026-03-04 SECtraded 2025-12-15

25,000

$399.2K

-4.5%

Context

15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Feb 21, 2025.
The trade is 50.0% of the 49,964 shares held after it.
No other insider sold within 30 days.
65 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: CHIEF MEDICAL OFFICER Morrell Martha sold about $399.2K of NPCE on Dec 15, 2025; 65 funds added in the latest 13F quarter.

ORBIMED ADVISORS LLC

SELL

2025-05-16 SECtraded 2025-05-14

34,000

$542.0K

-23.6%

Context

7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on May 3, 2024.
The trade is 1.0% of the 3,238,199 shares held after it.
No other insider sold within 30 days.
65 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Insider ORBIMED ADVISORS LLC sold about $542.0K of NPCE on May 14, 2025; 65 funds added in the latest 13F quarter.

ORBIMED ADVISORS LLC

SELL

2025-05-16 SECtraded 2025-05-14

134,136

$2.1M

-23.6%

Context

7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on May 3, 2024.
The trade is 4.1% of the 3,272,199 shares held after it.
No other insider sold within 30 days.
65 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Insider ORBIMED ADVISORS LLC sold about $2.1M of NPCE on May 14, 2025; 65 funds added in the latest 13F quarter.

Morrell Martha

CHIEF MEDICAL OFFICER

SELL

2025-02-25 SECtraded 2025-02-21

78,334

$1.1M

-3.6%

Context

14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Jan 30, 2025.
The trade is 95.5% of the 81,993 shares held after it.
1 other insider sold within 30 days.
65 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: CHIEF MEDICAL OFFICER Morrell Martha sold about $1.1M of NPCE on Feb 21, 2025; 1 other insider sold within 30 days and 65 funds added in the latest 13F quarter.

KCK LTD.

SELL

2025-02-20 SEC

5,270,845

$49.5M

-5.7%

Context

34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Oct 25, 2024.
1 other insider sold within 30 days.
65 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Insider KCK LTD. sold about $49.5M of NPCE on Feb 20, 2025, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 65 funds added in the latest 13F quarter.

71 transactions on record

Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.

Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.

See all insider buying · insider selling

Seven facts, ranked against the sector · Rank is not a forecast

Insiders

no insider buys or sells on file

Congress

no House purchase disclosed in the last 12 months

Funds

65 funds bought in last quarter

more than 51% of Medical Devices

Revenue

+25.1% year over year

more than 76% of Medical Devices

Margin

-21.5% net margin

below 54% of Medical Devices

Buybacks

$49.5M repurchased, FY to 2025-12-31

more than 51% of Medical Devices

Short interest

3.5% of the float short (float per yahoo 2026-10-26) · 6.2 days to cover · settled 2026-09-30

below 61% of Medical Devices

What changed in the last 30 days

Nothing new filed in the last 30 days

Watch NPCE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it

Total return over 12 months. Each marker is a filing; hover or tap one for the detail.

+23.1%12M

Insider sell

Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NPCE: institutional holders (13F)

13F holdings, latest reported quarter

Polar Capital Holdings Plc

3,298,104 sh

$52.4M

Soleus Capital Management, L.P.

2,911,122 sh

$46.3M

First Light Asset Management, LLC

2,861,167 sh

$45.5M

MORGAN STANLEY

2,654,391 sh

$42.2M

BlackRock, Inc.

2,477,603 sh

$39.4M

Congress trades in NPCE

No Congress trades reported

No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings

Nobody has filed for crossing 5%. That is a fact, not missing data.

NPCE planned insider sales (Form 144)

No planned-sale notices

No insider has filed to sell. Watch this after a run-up.

NPCE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).

1290 Essex Small Cap Growth Fund

$654.9K position · as of 2026-07-31

0.6%

Driehaus Micro Cap Growth Fund

$2.8M position · as of 2026-06-30

0.5%

Zacks Small-Cap Core Fund

$151.1K position · as of 2026-05-31

0.4%

State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF

$630.1K position · as of 2026-06-30

0.4%

NORTH SQUARE DYNAMIC SMALL CAP FUND

$1.5M position · as of 2026-05-31

0.2%

Adara Smaller Companies Fund

$1.4M position · as of 2026-05-31

0.2%

SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio

Clinical pipeline

5 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.

Phase 2

1 active

Not applicable

1 active

What changed recently

RNS System LGS Feasibility Study

2026-09-16 · Completion moved 2026-05-31 → 2026-11-30

Phase 2

Matched by sponsor name. Trials run under a subsidiary's own name are not included.

Live price

Daily candles from TradingView, under their licence. No filings marked.

Show the live price chart

Why this name is on the desk

The complete filing record, in one place.

The record shows 65 funds added last quarter. Each figure is a federal filing, dated the day it went public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector by SEC SIC code

PEN BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX OM IRMD

NPCE financials

Revenue growth

+25.1%

XBRL, annual

Net margin

-21.5%

Fundamentals

Annual figures from XBRL filings. Pick a past date to see them as known then.

	2025-12	2024-12	2023-12	2022-12
Revenue	$100.0M	$79.9M	$65.4M	$45.5M
Gross profit	$77.2M	$59.1M	$48.1M	$32.5M
Operating income	-$16.3M	-$21.7M	-$27.2M	-$40.8M
Net income	-$21.5M	-$27.1M	-$33.0M	-$47.1M
EPS (diluted)	-0.66	-0.93	-1.27	-1.91
Operating cash flow	-$11.0M	-$17.9M	-$19.7M	-$36.9M
Cash	$21.7M	$13.4M	$18.1M	$6.6M
Long-term debt	$58.9M	$59.5M	$57.0M	$52.9M
Buybacks	$49.5M	$0	n/a	n/a

SEC XBRL, fiscal years, as known on 2026-10-28

NPCE Stock Sonar score 5/7 axes

Find similar shapes Compare

NPCE ranks highest on risk and compliance (79th percentile) and growth (56th), and lowest on financial health (26th), among Medical Devices peers.

Profitability

Inputs

Return on equity-122.1% · 24 pct, sector of 183
Return on assets-18.8% · 46 pct, sector of 214
Return on invested capitalthe filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employedthe filed year and its quarters do not reconcile, so the trailing figure is withheld

Financial health

Inputs

Debt to equity4.97x · 4 pct, sector of 159
Cash flow to debt-0.19x · 48 pct, sector of 150

Growth

Inputs

Revenue growth, YoY+25.1% · 76 pct, sector of 219
Backlog growth, YoY+0.0% · 36 pct, sector of 37

Institutional and government

Inputs

Funds adding, latest quarter65 · 51 pct, sector of 191
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quarters$160K · 37 pct, sector of 50

Risk and compliance

Inputs

Short interest, % of float+3.5% · 59 pct, sector of 240
Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+5.8% · 78 pct, sector of 198

2 not measured: Insider conviction, US patents

Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing

Insider buying Insider selling Congress stock trades Activist 13D stakes Form 144 planned sales CEO pay vs performance All companies

FY Dec 2025	$100.0M
FY Dec 2024	$79.9M
FY Dec 2023	$65.4M
FY Dec 2022	$45.5M
FY Dec 2021	$45.2M

Jun 2026	$22.8M
Mar 2026	$22.1M
Dec 2025	$26.6M
Sep 2025	$27.4M
Jun 2025	$23.5M
Mar 2025	$22.5M
Dec 2024	$21.5M
Sep 2024	$21.1M

FY Dec 2025	-21.5%
FY Dec 2024	-34.0%
FY Dec 2023	-50.4%
FY Dec 2022	-103.4%
FY Dec 2021	-79.9%

Jun 2026	-27.2%
Mar 2026	-30.3%
Dec 2025	-10.3%
Sep 2025	-12.8%
Jun 2025	-36.8%
Mar 2025	-29.3%
Dec 2024	-24.5%
Sep 2024	-25.9%

FY Dec 2025	-$11.3M
FY Dec 2024	-$18.3M
FY Dec 2023	-$19.9M
FY Dec 2022	-$37.5M
FY Dec 2021	-$25.0M

Jun 2026	-$4.0M
Mar 2026	-$6.0M
Dec 2025	$409.0K
Sep 2025	-$2.0M
Jun 2025	-$2.3M
Mar 2025	-$7.5M
Dec 2024	-$4.8M
Sep 2024	-$1.8M

FY Dec 2025	3.09x
FY Dec 2024	7.43x
FY Dec 2023	2.76x
FY Dec 2022	1.52x
FY Dec 2021	0.68x

Jun 2026	4.97x
Mar 2026	4.08x
Dec 2025	3.09x
Sep 2025	3.17x
Jun 2025	3.02x
Mar 2025	2.46x
Dec 2024	7.43x
Sep 2024	6.03x

FY Dec 2025	-0.19x
FY Dec 2024	-0.30x
FY Dec 2023	-0.35x
FY Dec 2022	-0.70x
FY Dec 2021	-0.49x

FY Dec 2025	-158.7%
FY Dec 2024	-189.4%
FY Dec 2023	-118.9%
FY Dec 2022	-87.0%
FY Dec 2021	n/a

Jun 2026	-122.1%
Mar 2026	-111.4%
Dec 2025	-158.7%
Sep 2025	-169.3%
Jun 2025	-176.9%
Mar 2025	-128.5%
Dec 2024	-189.4%
Sep 2024	-214.5%

FY Dec 2025	-21.4%
FY Dec 2024	-26.8%
FY Dec 2023	-29.7%
FY Dec 2022	-38.0%
FY Dec 2021	-38.1%

Jun 2026	-18.8%
Mar 2026	-20.6%
Dec 2025	-21.4%
Sep 2025	-23.6%
Jun 2025	-25.9%
Mar 2025	-23.7%
Dec 2024	-26.8%
Sep 2024	-28.7%

FY Dec 2025	n/a
FY Dec 2024	-25.4%
FY Dec 2023	-27.9%
FY Dec 2022	-35.9%
FY Dec 2021	-27.8%

FY Dec 2025	$551.5M
FY Dec 2024	$380.1M
FY Dec 2023	$309.9M
FY Dec 2022	$83.4M
FY Dec 2021	$275.7M

Jun 2026	$588.2M
Mar 2026	$487.0M
Dec 2025	$551.5M
Sep 2025	$379.2M
Jun 2025	$401.1M
Mar 2025	$432.9M
Dec 2024	$380.1M
Sep 2024	$247.4M

FY Dec 2025	-2.2%
FY Dec 2024	-5.5%
FY Dec 2023	-7.3%
FY Dec 2022	-101.0%
FY Dec 2021	-10.2%

Jun 2026	-2.1%
Mar 2026	-2.2%
Dec 2025	-2.2%
Sep 2025	-4.9%
Jun 2025	-4.5%
Mar 2025	-4.5%
Dec 2024	-5.5%
Sep 2024	-8.3%